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Abstract
Background: Prostate cancer (PCa) cells preferentially metastasize to bone at least in part by acquiring
osteomimetic properties. Runx2, an osteoblast master transcription factor, is aberrantly expressed in PCa cells, and
promotes their metastatic phenotype. The transcriptional programs regulated by Runx2 have been extensively
studied during osteoblastogenesis, where it activates or represses target genes in a context-dependent manner.
However, little is known about the gene regulatory networks influenced by Runx2 in PCa cells. We therefore
investigated genome wide mRNA expression changes in PCa cells in response to Runx2.
Results: We engineered a C4-2B PCa sub-line called C4-2B/Rx2
dox, in which Doxycycline (Dox) treatment stimulates
Runx2 expression from very low to levels observed in other PCa cells. Transcriptome profiling using whole genome
expression array followed by in silico analysis indicated that Runx2 upregulated a multitude of genes with
prominent cancer associated functions. They included secreted factors (CSF2, SDF-1), proteolytic enzymes (MMP9,
CST7), cytoskeleton modulators (SDC2, Twinfilin, SH3PXD2A), intracellular signaling molecules (DUSP1, SPHK1,
RASD1) and transcription factors (Sox9, SNAI2, SMAD3) functioning in epithelium to mesenchyme transition (EMT),
tissue invasion, as well as homing and attachment to bone. Consistent with the gene expression data, induction of
Runx2 in C4-2B cells enhanced their invasiveness. It also promoted cellular quiescence by blocking the G1/S phase
transition during cell cycle progression. Furthermore, the cell cycle block was reversed as Runx2 levels declined
after Dox withdrawal.
Conclusions: The effects of Runx2 in C4-2B/Rx2
dox cells, as well as similar observations made by employing LNCaP,
22RV1 and PC3 cells, highlight multiple mechanisms by which Runx2 promotes the metastatic phenotype of PCa
cells, including tissue invasion, homing to bone and induction of high bone turnover. Runx2 is therefore an
attractive target for the development of novel diagnostic, prognostic and therapeutic approaches to PCa
management. Targeting Runx2 may prove more effective than focusing on its individual downstream genes and
pathways.
Introduction
Runx2 together with Runx1 and Runx3 comprise the
Runx class of transcription factors, defined by their
highly homologous Runt-related DNA-binding domain.
As heterodimers with Cbfß, Runx proteins bind to cog-
nate DNA elements with the consensus nucleotide
sequence 5’-ACCACA in the promoters/enhancers of
their target genes [1]. The three Runx proteins coordi-
nate proliferation and differentiation of various cell
types [2]. Runx1 is important for hematopoiesis [3,4];
Runx2 is pivotal in osteogenesis [1,5,6]; and Runx3 is
critical for neurogenesis [7], thymopoiesis [4], and main-
tenance of the gastric epithelium [4,8]. While promoting
specific cellular phenotypes, Runx proteins have evolved
to inhibit cell proliferation. Runx3 is a bona fide tumor
suppressor [9] as down-regulation of its promoter by
hypermethylation contributes to the development of gas-
tric cancer [10,11]. Ablation of Runx1 activity leads to
leukemia [12] and disruption of Runx2 results in
deregulated cell proliferation and immortalization
[13-17]. Paradoxically, Runx2 is also implicated in carci-
nogenesis. In a mouse screen for c-Myc-collaborating
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quently when the provirus integrated into the Runx2
locus resulting in its ectopic expression [18]. It was sug-
gested that Runx2 initially provides the cells with a sur-
vival advantage, and its anti-mitogenic activity is
counteracted by the CD2-Myc transgene present in the
mouse model used for this screen [2,19]. Therefore,
Runx2-mediated tumorigenesis likely requires additional
loss of check-point genes such as Trp53 or improper
regulation of an oncogene such as c-Myc [19].
Runx2 has been extensively studied in the context of
osteoblastogenesis from mesenchymal progenitors,
where as a master regulator it stimulates the expression
of various bone matrix components such as osteocalcin
and bone sialoprotein (BSP) [20]. Runx2
-/- mice die
soon after birth due to the lack of differentiated osteo-
blasts and thus a mineralized skeleton [1,5,6]. Runx2
haploinsufficiency in humans causes the rare skeletal
disorder Cleidocranial Dysplasia [21]. In search for
hints to explain the high predilection of prostate and
breast cancer to metastasize to bone, investigators have
noticed ectopic expression of Runx2 and some of its tar-
get genes in biopsies from advanced tumors and their
derivative cell lines [22-26]. In a mouse model of PCa,
conditional deletion of Pten in prostate epithelial cells
resulted in the development of tumors with progressive
increase in Runx2 expression [27]. Among the osteomi-
metic properties of prostate and breast cancer cells are
expression of the Runx2 target genes MMP9 [28], BSP
[29] and VEGFA [30], as well as induction of minerali-
zation [25].
In addition to promoting osteoblast differentiation,
Runx2 drives the expression of osteoclastogenic signals,
both in osteoblasts [31,32] and in the PC3 bone metas-
tasis-derived PCa cell line [22]. PC3 cells robustly
express Runx2 [33], and its silencing decreased their
osteoclastogenic property in vitro and their growth
within the bone microenvironment in vivo [22]. Runx2
also promotes metastatic aspects not necessarily related
to bone. Invasion of PC3 cells through Matrigel™,a
basement membrane-like preparation, decreased after
Runx2 silencing [22], and its ectopic expression in
mammary epithelial cells increased their proliferation
and disrupted their normal acinar organization [34]. An
oncogenic role for Runx2 has also been suggested in
tumors that do not exhibit high predilection to bone,
including pancreatic ductal adenocarcinoma [35] and
thyroid papillary carcinoma [36].
Whereas Runx2 is being increasingly recognized as a
pro-metastatic factor, little is known about the underly-
ing transcriptional programs. To establish gene regula-
tory networks downstream of Runx2 in aggressive PCa,
we analyzed gene expression in response to Runx2 in
the C4-2B PCa cell line. These cells are castration-
resistant derivatives of the androgen-dependent LNCaP
cells, and serve as a model for the aggressive stage of
bone metastatic PCa [37,38]. Although C4-2B cells
express Runx2 at levels higher than LNCaP cells [25],
these levels are far lower than those observed in PC3
cells or osteoblasts [22]. We therefore engineered a C4-
2B sub-line that allowed us to profile gene expression
after induction of Runx2 with Doxycycline to levels seen
in PC3 cells. Remarkably, the most significant changes
were the up-regulation of genes implicated in cancer
progression and cellular movement, and the down-regu-
lation of genes involved in cell cycle progression. Con-
sistent with these changes in gene expression, Runx2
enhanced PCa cell invasiveness and inhibited their
proliferation.
Results and Discussion
Establishment of C4-2B PCa cells with conditional Runx2
expression
To establish a C4-2B cell line that conditionally
expresses Runx2, we employed the recently described
lentivirus-based pSLIK vector system, which allows tight
Doxycycline (Dox)-inducible, RNA PolII-mediated tran-
scription of a gene of interest [39]. C4-2B cells were
transduced with Flag-tagged Runx2-encoding lenti-
viruses (Figure 1A), resulting in the C4-2B/Rx2
dox sub-
line. As control, we established the C4-2B/Rx2-M
dox
subline, where Dox treatment induced expression of the
transcriptionally inactive Flag-Runx2-M (Figure 1A)
[40]. Western blot analysis with anti-Flag antibodies
confirmed roughly equal expression levels of the wild
type and mutant Runx2 proteins, which were strictly
and dose-dependently regulated by Dox (Figure 1B).
RT-qPCR analysis revealed that the Dox treatment
increased Runx2 mRNA by ~20-fold compared to its
endogenous levels, and that the induced level was com-
parable to that observed in the PC3
high sub-line (Figure
1C). Western analysis using anti-Runx2 antibodies indi-
cated that the level of endogenous Runx2 protein was
negligible in untreated C4-2B cells, and that Dox
induced expression of the exogenous Runx2 to the levels
normally found in osteoblasts (Figure 1D) [41].
The transcriptional activity of Dox-induced Runx2 was
initially assessed using luciferase reporter assay (Figure
1E). In the reporter plasmid 6XOSE2-Luc, luciferase
expression was controlled by six copies of the osteo-
blast-specific element 2 (OSE2) from the Runx2-regu-
lated osteocalcin (OC) gene promoter [42]. In the
absence of Dox, 6XOSE2-luc activity was indistinguish-
able from the background luciferase activity observed
without any cell extract, suggesting lack of endogenous
Runx2 activity (Figure 1E). The luciferase reporter was
strongly stimulated by WT but not by the mutant form
of Runx2 (Figure 1E). As shown in Figure 1F, Runx2
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genes Bone Sialoprotein (BSP) [29] and Matrix Metallo-
protease-9 (MMP9) [28]. These genes were not stimu-
lated in the Dox-treated C4-2B/Rx2-M
dox cells (data not
shown). Interestingly, Runx2 did not significantly
enhance the expression of OC (Figure 1F) and Alkaline
Phophatase (ALP; data not shown), although these
genes are strongly stimulated by Runx2 in osteoblasts
[1,43]. This observation reflects cell type-dependent
Runx2-mediated transcriptional control, and is consis-
tent with the results of Yeung et al.[ 3 3 ] ,w h od e m o n -
strated that in PC3 cells the OC promoter is responsive
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Figure 1 Establishment of C4-2B/Rx2
dox sub-line with conditional Runx2 expression. A, Schematic diagram of the pSLIK-based lentiviral
vector. Initially developed for expression of shRNAs [39] the pSLIK vector was used in the present study to express Runx2. The Hygromycin
resistance marker (Hyg) and the Dox-dependent activator protein rtTA3 are constitutively expressed under the control of the Ubi-c promoter.
Upon treatment with Dox, rtTA binds to its tetracycline responsive elements (TRE) and drives expression of the inserted cDNA (Flag-Runx2). The
Runx2 block diagram depicts its glutamine/alanine-rich QA domain, the DNA-binding Runt domain, and the proline/serine/threonine-rich PST
domain. Arrowhead indicates the position of the R265D and R268D mutations in Runx2-M, which eliminate Runx2’s DNA binding function. B,
Whole cell extracts, prepared from C4-2B/Rx2
dox and C4-2B/Rx2-M
dox cells treated with the indicated concentrations of Dox, were subjected to
western blot analysis using anti-Flag antibodies. C, Total RNA was extracted from C4-2B/Rx2
dox cells treated with Dox or vehicle, as well as from
PC3
high cells, and the mRNA levels of Runx2 (and GAPDH as control) were measured by RT-qPCR. D, Whole cell extracts were prepared from C4-
2B/Rx2
dox cells treated with Dox as indicated and from ROS 17.8/2 osteoblastic cells [41], and subjected to western blot analysis using anti-Runx2
antibodies. The same blot was re-probed with anti-Tubulin antibodies as loading control. E, C4-2B/Rx2
dox and C4-2B/Rx2-M
dox cells were
transiently transfected with the 6XOSE2-luciferase reporter plasmid and subjected to luciferase assay. Dotted line represents the background
luciferase activity with no cell extract. F, C4-2B/Rx2
dox cells were treated with Dox and levels of the indicated transcripts were measured by RT-
qPCR and corrected for that of GAPDH. In Figure 1, bars represent Mean ± SEM (n = 3) from a representative experiment, which was repeated at
least three times with similar results. Abbreviations used: Dox, Doxycycline; Veh, vehicle; BSP, Bone Sialoprotein; MMP9, Matrix Metalloprotein-9;
OC, Osteocalcin.
Baniwal et al. Molecular Cancer 2010, 9:258
http://www.molecular-cancer.com/content/9/1/258
Page 3 of 18to the transcription factors AP-1 and SP1, but not
Runx2. To identify Runx2-regulated genes and pathways
in advanced PCa cells in an unbiased manner, we sub-
jected C4-2B/Rx2
dox cells to global gene expression
profiling.
Runx2-regulated global gene expression and in silico
assessment of associated pathways
C4-2B/Rx2
dox cells were subjected to microarray gene
expression analysis after one- and two- days of treat-
ment with either Dox or vehicle in biological quadrupli-
cates (a total of 16 samples). Of 24,526 probes
represented in the microarray, 532 genes showed ≥2-
fold increased expression and 378 genes showed ≥2-fold
decreased expression with high statistical significance
(p < 0.008) on either day of treatment (see additional
file 1). RT-qPCR analysis of 50 representative genes con-
formed to the microarray data (Table 1 and additional
file 2).
An unsupervised hierarchical analysis of these 910 up-
and down-regulated genes resulted in a clear separation
between the Dox-treated and control samples (Figure 2).
The variation among the biological quadruplicates was
small, indicating the overall robustness of the methodol-
ogy utilized. Gene clusters showing changes in expres-
sion pattern with respect to time and Dox treatment
were clearly discernable. In general, changes observed
on day 1 of treatment were maintained or intensified by
day 2.
We next employed the Ingenuity Pathway Analysis
(IPA™) platform to indentify disease pathways, as well as
molecular and cellular functions associated with Runx2-
regulated genes. The analysis suggested ‘cancer’ as the
disease most significantly associated with both the up-
and the down-regulated gene groups (Table 2). A total
of 248 genes, half from each group, had highly signifi-
cant cancer related function (see additional file 3). Addi-
tionally, the up-regulated genes were strongly associated
with genetic disorders, inflammatory responses, and gas-
trointestinal diseases (Table 2A). Among the most sig-
nificant molecular and cellular functions, cellular
movement, cell death, cellular growth, and proliferation
were associated with the up-regulated genes, whereas
cell cycle, cell death, cellular assembly and DNA replica-
tion functions were associated with the down-regulated
genes (Table 2B).
Runx2-modulated genes are involved in tumor metastasis
Promotion of tissue invasion, metastasis and cytoskeleton
dynamics
The major functions reported for the up-regulated genes
belonged to cancer progression (Table 2). Importantly,
these genes encode transcriptional regulators, cytoskele-
tal components, signaling molecules and peptidases,
which have been implicated in tumor metastasis (Table
1). The transcription factors Sox9 and SNAI2, and the
extracellular-matrix (ECM) protein LCN2, all major reg-
ulators of epithelial-to-mesenchymal transition (EMT)
[44,45], were up-regulated by ~4-fold after one day and
by > 6-fold after two days of Runx2 induction, and their
upregulation was confirmed by RT-qPCR (Table 1).
However, the functional significance of these EMT mar-
kers requires further investigation in light of the unex-
pected increase in E-cadherin mRNA (see additional file
4). Runx2 also enhanced the expression levels of multi-
ple transcripts encoding matrix modifying peptidases
(Table 1). These included MMP9, a known Runx2 target
in BCa cells [28] and aspartyl proteases with fibronectin
degrading activities such as Prolactin Induced Protein
(PIP) and Pepsinogen (PGC) [46,47]. The latter two
showed a rapid ~10-fold increase within 24 hours
(Table 1) and PIP exhibited the highest change (79-fold)
in response to Runx2 on day 2 (Table 1 and additional
file 2). PIP protein in the C4-2B/Rx2
dox culture superna-
tant was below detectable levels under control condi-
tions, but was readily detected after induction of Runx2
(Figure 3). We also found increased transcript levels for
Cystatin 7 (CST7), S100A4 and SMAD3, with a mild
~3-fold increase on day 1, but a robust > 20-fold
increase on day 2 (Table 1). These genes function as
metastasis promoters [48,49]. Interestingly, S100A4 and
SMAD3 physically interact to potentiate cancer cell
invasiveness [50].
Runx2 also up-regulated genes involved in cellular
movement and cytoskeleton remodeling (Table 1).
SH3PXD2A, which was up-regulated by 7-fold on day 2,
is a scaffold protein involved in the formation of invado-
pedia [51,52], which are matrix digesting, actin rich,
short lived protrusions observed in osteoclasts and can-
cer cells [53]. Runx2 up-regulated by > 9-fold the tran-
scripts for Nav2, a scaffold protein crucial for actin
cytoskeleton remodeling [53]. Other genes that were up-
regulated by > 3-fold, with known roles in actin cytoske-
leton dynamics included ESPN, which interacts with the
Src-homology 3 (SH3) adaptor proteins to regulate
cytoskeletal actin functions [54]; MAP1B, known to
maintain cytoskeletal integrity [55]; LIMA1, which
cross-links actin monomers [56]; and PTK9L (a.k.a.
twinfiln), which sequesters ADP-actin monomers in the
cytoplasm and delivers them to sites of rapid actin-fila-
ment assembly [57].
Metastasis to bone and modification of the bone
microenvironment
The expression of SDF-1 and its receptor CXCR7 was
enhanced by > 5-fold based on the microarray analysis
and by > 20-fold based on the RT-qPCR results (Table
1). Runx2-induced SDF-1 protein was also detectable in
the culture supernatant (Figure 3). SDF-1 signaling is
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Page 4 of 18Table 1 Genes most responsive to Runx2 in C4-2B cells
Gene
ID
Symbol Gene Name Anova Fold
change
Description of cancer related or other major function Reference
p value II Iq
Transcription regulators
7069 THRSP Thyroid hormone
responsive
3.5E-06 7 5 Transcription of enzymes involved in tumor lipid
metabolism
29947 DNMT3L DNA (cytosine-5-
)-methyltransferase
3-like
5.5E-08 5 6 >
50
DNA methylation, nucleic acid metabolic process
4091 SMAD6 SMAD family
member 6
8.1E-10 5 4 Cell communication, TGF-beta receptor signaling
pathway
6591 SNAI2 Snail homolog 2
(Drosophila)
8.8E-07 4 12 6 Promotes EMT by repressing E-cadherin transcription [44]
6662 SOX9 SRY (sex
determining region
Y)-box 9
4.4E-07 4 6 17 Promotes chondrocyte differentiation, cell migration, and
EMT
[110]
7025 NR2F1 Nuclear receptor
subfamily 2,
3.5E-07 3 14 2 Ligand-dependent receptor, regulation of transcription
termination
678 ZFP36L2 Zinc finger protein
36, C3H type-like 2
4.1E-09 3 10 Regulation of RNA metabolic process
4088 SMAD3 SMAD family
member 3
6.3E-10 3 7 25 Signal transducer downstream of TGF-b receptors
283248 RCOR2 REST corepressor 2 2.9E-06 3 7 Negative regulation of transcription
10217 CTDSPL Small CTD
phosphatase 3
1.9E-09 -2 -3 Phosphatase, dephosphorylates Rb, suppresses cellular
growth
1870 E2F2 E2F transcription
factor 2
8.2E-10 -2 -5 -4 Transcription activator, regulation of cell cycle
progression, proliferation
90390 MED30 Mediator complex
subunit 30
< 1.0E-12 -2 -3 Transcription activator, Androgen receptor signaling
pathway
4609 MYC V-myc
myelocytomatosis
viral oncogene
2.9E-07 -2 -3 -2 Positive regulation of cell proliferation, apoptosis [111,112]
29893 PSMC3IP PSMC3 interacting
protein
3.5E-08 -2 -4 Gene expression from RNA PolII
4602 MYB Viral oncogene
homolog (avian)
1.6E-08 -3 -5 -3 G1/S transition of mitotic cell cycle
4824 NKX3-1 NK3 homeobox 1 3.7E-08 -3 -3 Transcription repressor, loss induces prostate
tumorigenesis
Intracellular signaling, cell cycle and proliferation
51655 RASD1 RAS,
dexamethasone-
induced 1
6.8E-12 26 19 >
50
Ras related, suppresses cell proliferation, inhibits tumor
growth
[92]
6446 SGK Serum/
glucocorticoid
regulated kinase 1
< 1.0E-12 19 45 Cellular Na
+ ion homeostasis, cell survival
57007 CXCR7 Chemokine
receptor 7
9.2E-11 8 12 30 Receptor for SDF-1, GPCR, enhanced integrin activation
and tumor growth
[113]
1843 DUSP1 Dual specificity
phosphatase 1
9.1E-13 8 8 10 Regulator of cell cycle, response to stress [114]
5580 PRKCD Protein kinase C,
delta
2.0E-11 6 5 12 Serine-Threonine Kinase, cell proliferation, cell
contraction
55890 GPRC5C G protein-coupled
receptor, family C
1.3E-09 5 5 25 GPCR, cell communication
10461 MERTK C-mer proto-
oncogene tyrosine
kinase
6.2E-10 4 6 39 Protein amino acid phosphorylation
5920 RARRES3 Retinoic acid
receptor responder
3
4.3E-08 3 8 40 Negative regulation of cell proliferation
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1903 EDG3 Sphingosine-1-
phosphate
receptor 3
4.8E-10 3 7 GPCR, enhances tumor growth, cell migration, and
angiogenesis
[77-79,115,116]
8877 SPHK1 Sphingosine kinase
1
7.5E-09 3 12 36 Kinase for the production of S1P, enhances tumor
growth, cell migration, and angiogenesis, PCa cell
survival against chemotherapy, osteoclast chemotaxis
[77-79,115,116]
7049 TGFBR3 Transforming
growth factor, b
receptor III
7.1E-09 3 4 12 Negative regulation of TGFb receptor signaling pathway
4921 DDR2 Discoidin domain
receptor tyrosine
kinase 2
2.9E-05 2 5 Collagen binding, cell proliferation
1017 CDK2 Cyclin-dependent
kinase 2
1.3E-03 -2 -3 -4 Kinase, mitotic cell cycle, cell proliferation
55038 CDCA4 Cell division cycle
associated 4
7.2E-08 -2 -4 -4 Repressor of E2F-dependent transcriptional activation
and cell proliferation
5997 RGS2 Regulator of G-
protein signaling 2,
24 kDa
9.0E-09 -3 -3 Cell cycle, GPCR signaling pathway, cell communication
25805 BAMBI BMP and activin
membrane-bound
inhibitor homolog
(Xenopus laevis)
9.7E-10 -2 -3 TGF-b signaling pathway
Cellular movement, adhesion, invasion, cytoskeleton remodeling
89797 NAV2 Neuron navigator 2 6.7E-09 9 10 29 Scaffold protein, actin cytoskeleton remodeling, nervous
system development
[53]
27111 SDCBP2 Syndecan binding
protein 2
2.2E-03 6 15 Binds SDC2, regulates cell adhesion and communication
with ECM molecules
[84,85]
11344 PTK9L Twinfilin 9.0E-10 6 5 11 Actin-binding protein, cytoskeleton organization [57]
83715 ESPN Espin 2.1E-08 5 8 >
50
Actin-binding-bundling protein, actin cytoskeleton
dynamics, cell locomotion
[54,117,118]
51474 LIMA1 Eplin, LIM domain
and actin binding
1
3.0E-10 4 5 15 Cytoskeleton-associated protein, regulation of actin
filament depolymerization
[56]
8829 NRP1 Neuropilin 1 4.1E-08 4 11 40 TM, coreceptor for VEGF, collagen binding, cell adhesion,
invasion
[119]
4582 MUC1 Mucin 1, cell
surface associated
1.1E-09 4 4 TM, cell adhesion, invasion [120]
4131 MAP1B Microtubule-
associated protein
1B
7.1E-09 3 9 18 Trans-membrane glycoprotein, cytoskeleton organization [55,121]
9644 SH3PXD2A SH3 and PX
domains 2A
1.4E-09 3 7 Adaptor protein, ECM degradation by actin based
invadopedia formation
[122]
6275 S100A4 S100 calcium
binding protein A4
2.6E-08 2 24 >
50
EF-hand calcium-binding protein, promotes cell motility,
tumor metastasis
[49]
6383 SDC2 Syndecan 2 3.1E-06 2 5 32 TM, bind signaling factors, cell adhesion, angiogenesis,
ECM degradation
[84,85]
1013 CDH15 Cadherin 15, type
1, M-cadherin
6.9E-08 2 5 21 TM, Ca
2+dependent intercellular adhesion, skeletal
muscle development
[123]
Secreted factors
1437 CSF2 Colony stimulating
factor 2/GM-CSF
2.3E-09 12 17 >
50
Cytokine, osteolytic bone metastasis [72]
5225 PGC Progastricsin
(pepsinogen C)
3.9E-12 11 15 Aspartyl proteinase [47]
5304 PIP Prolactin-induced
protein
< 1.0E-12 10 79 >
50
Aspartyl proteinase, ligand for CD4 receptor T cells [46]
8857 FCGBP Fc fragment of IgG
binding protein
1.5E-09 5 9 Cell adhesion, cell-cell recognition
6387 CXCL12 Chemokine ligand
12 (SDF-1)
2.2E-06 5 7 23 Chemokine, stem cell trafficking to bone, migration,
metastasis of tumor cells
[58-65]
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Page 6 of 18critical for homing of hematopoietic cells to the bone
marrow space and their survival in this environment
[58-65]. Within one day, Runx2 also increased by 10-
fold the mRNA for BSP (Figure 1F), whose abundant
expression by bone metastatic tumor cells facilitates
their attachment to the bone matrix [66-69]. Once
settled in the bone microenvironment, the metastatic
cells secrete regulatory molecules that stimulate bone
turnover [70]. Remarkably, Runx2 enhanced the expres-
sion of the osteoclastogenic cytokine CSF2 by > 50-fold
within 48 hours (Table 1). This presumably occurred by
direct binding of Runx2 to the CSF2 promoter [71].
Runx2-mediated induction of CSF2 in PCa cells likely
contributes to the increased bone turnover in bone
metastatic sites, similar to the role of this cytokine in
breast cancer bone metastasis [72]. CSF2 production by
tumor cells may also contribute to accumulation of
macrophages, inflammatory T cells, and cytokines
[73,74] that exacerbate morbidity and mortality [75].
Two additional Runx2-up-regulated genes associated
with osteoclast function are SPHK1, a kinase responsible
for the production of sphingosine 1 phosphate (S1P),
and S1P receptor 3 (S1P3) a.k.a. EDG3 (Table 1). Pro-
duction of S1P in the bone microenvironment promotes
Table 1 Genes most responsive to Runx2 in C4-2B cells (Continued)
7422 VEGFA Vascular
endothelial growth
factor A
4.5E-10 5 3 4 Growth factor, angiogenesis, cellular morphogenesis
during differentiation
[88-91]
1907 EDN2 Endothelin 2 4.3E-07 5 2 Growth factor, vasoactive, G-protein signaling, smooth
muscle contraction
[87]
5654 HTRA1 HtrA serine
peptidase 1
6.9E-10 3 18 Serine protease, differentially expressed in osteoarthritic
cartillage
[124]
3817 KLK2 Kallikrein-related
peptidase 2
1.5E-08 4 3 Serine protease, protein metabolic process
4880 NPPC Natriuretic peptide
precursor C
1.8E-10 4 17 >
50
Peptide, potent natriuretic, diuretic, and vasodilating
7057 THBS1 Thrombospondin 1 3.0E-10 4 14 >
50
Cell adhesion, heparin-binding, anti-angiogenic
3934 LCN2 Lipocalin 2 5.1E-08 4 10 5 ECM protein, present ligands to cell surface receptors,
promotes EMT
[45]
6462 SHBG Sex hormone-
binding globulin
8.7E-10 4 10 Steroid-binding, signal
57642 COL20A1 Collagen, type XX,
a 1
4.9E-07 4 10 >
50
Adhesion, establishment of localization, transport
4254 KITLG KIT ligand 2.3E-08 4 7 41 Hematopoietic growth factor and ligand for the KIT
tyrosine kinase receptor
4884 NPTX1 Neuronal pentraxin
I
2.5E-07 3 20 Cell-cell signaling, transport, establishment of localization
3486 IGFBP3 IGF binding
protein 3
2.2E-08 3 7 Regulation of cell growth, communication, apoptosis
9806 SPOCK2 Sparc/osteonectin,
cwcv, kazal-like
domains
proteoglycan
(testican) 2
1.1E-06 3 4 Cell differentiation, ECM organization and biogenesis
8530 CST7 Cystatin F
(leukocystatin)
3.0E-09 2 25 Competitive inhibitors of cysteine proteases, metastasis
associated protein
[48]
4885 NPTX2 Neuronal pentraxin
II
7.6E-09 2 6 Cell-cell signaling, synaptic transmission
147381 CBLN2 ADAM MMP with
Thbs-1 motif
5.2E-12 -3 -3 Peptidase, cleavage of precerebellin in the nervous
system
6781 STC1 Spondin 2 3.6E-08 -3 -3 ECM protein, integrin ligand, pattern recognition
7035 TFPI Tissue factor
pathway inhibitor
3.9E-05 -3 -4 Kunitz-type inhibitor of blood coagulation by blocking
factor Xa
9518 GDF15 Growth
differentiation
factor 15
1.6E-09 -2 -8 -7 Growth factor, TGF-b signaling pathway, cell
communication
Fold changes on day 1 and day 2 are listed in columns I and II respectively, and column q lists fold changes based on RT-qPCR analysis of the day-2 samples.
Major gene functions were determined using knowledge databases from OMIM (Online Mendelian Inheritance of Man), IPA™ systems and the indicated
referenced literature. Abbreviations: EMT, epithelial to mesenchymal transition; TM, transmembrane; GPCR, G-protein coupled receptor; ECM, extracellular matrix.
Baniwal et al. Molecular Cancer 2010, 9:258
http://www.molecular-cancer.com/content/9/1/258
Page 7 of 18bone resorption by chemotactically attracting osteoclast
precursors [76]. The SPHK1/S1P/S1P3 axis plays addi-
tional roles in cancer progression, including cell growth,
migration, angiogenesis, and resistance to chemotherapy
[77-79]. Notably, Runx2 was the only gene differentially
up-regulated in chemotherapy-resistant versus -sensitive
osteosarcoma tumors [80]. Adding to this, Runx2 also
repressed the expression of GDF-15, an osteoclastogen-
esis inhibitor [81] (Table 1). This repression was mild
on day 1 (2-fold), but by day 2 GDF-15 was the most
repressed gene in response to Runx2 (8-fold; Table 1
and additional file 2). Thus, Runx2-mediated alterations
in gene expression may contribute to both the predilec-
tion of PCa to bone and the subsequent pathological
increase in bone turnover, which further fuels growth of
the metastatic tumors.
Angiogenesis
Runx2 has been implicated in promoting angiogenesis
by stimulating VEGFA expression during bone develop-
ment [30] as well as during tumorigenesis [82]. In
C4-2B/Rx2
dox cells, Runx2 increased VEGFA mRNA by
4-fold (Table 1) and the presence of VEGF in the cell
culture supernatant was detectable only after Dox treat-
ment (Figure 3). Additionally, our study revealed a 32-
fold upregulation of the VEGFA co-receptor Syndecan-2
(SDC2; Table 1). SDC2, which is also a Runx2 target in
osteoprogenitor cells [83], is a member of the heparan
sulfate proteoglycans family, and is also implicated in
cell adhesion and communication [84-86]. Interestingly,
VEGFA can functionally synergize with SDF-1 to pro-
mote neoangiogenesis in vivo [62]. Our microarray ana-
lysis also revealed Runx2-mediated induction of the
angiogenic EDN-2 gene (Table 1). Endothelins and
5
3
2
 
g
e
n
e
s
 
i
n
d
u
c
e
d
 
≥
2
-
f
o
l
d
 
3
7
8
 
g
e
n
e
s
 
r
e
p
r
e
s
s
e
d
 
≥
2
-
f
o
l
d
C
o
l
o
r
 
c
o
d
e
p
≤
0
.
0
0
8
p
≤
0
.
0
0
8
Figure 2 Unsupervised hierarchical clustering of differentially
expressed genes. Genes that Runx2 up- or down-regulated by ≥2-
fold on either day 1 or day 2 (total: 910 genes) with p < 0.008 were
subjected to pearson’s centered correlation matrix. Heatmap
represents intensity values relative to the median intensity across all
16 samples per probe after background subtraction and
normalization.
Table 2 Diseases, Molecular and Cellular Functions
associated with genes up-regulated (A) and down-
regulated (B) by Runx2
A) ≥ 2 fold up-regulated, total 532 genes p-value genes
Diseases and disorders
Cancer 2.5e
-07 - 3.0e
-03 124
Genetic disorder 5.4e
-07 - 3.0e
-03 229
Inflammatory response 3.3e
-06 - 2.4e
-03 65
Molecular and cellular functions
Cellular movement 9.7e
-12 - 2.5e
-03 84
Cell death 2.6e
-10 - 3.2e
-03 129
Cellular growth, proliferation 9.3e
-08 - 3.2e
-03 108
B) ≥ 2 fold down-regulated, total 378 genes
Diseases and disorders
Cancer 3.3e
-29 - 4.1e
-03 124
Gastrointestinal disease 3.3e
-29 - 3.7e
-03 72
Genetic disorder 3.3e
-06 - 3.4e
-03 174
Molecular and cellular functions
Cell cycle 7.1e
-35 - 4.1e
-03 102
Cellular assembly, organization 1.7e
-18 - 3.4e
-03 63
DNA replication, recombination, repair 1.7e
-18 - 4.1e
-03 101
IPA™ analysis indicating the association of Runx2-regulated genes to a
particular category identifying the indicated disease or function. The ranges of
p values indicate the statistical significance with which Runx2-regulated genes
associate with the each category.
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Page 8 of 18VEGFA are secreted by PCa cells to stimulate angiogen-
esis as well as differentiation of neighboring osteoblasts
in the bone microenvironment [72,87-91].
Runx2 increases the invasion potential of C4-2B cells
in vitro
Because Runx2 enhanced the expression of multiple
extracellular enzymes involved in ECM degradation
(Table 1), we initially tested by in-gel zymography the
presence of proteases in the supernatant of Dox-treated
C4-2B/Rx2
dox cultures. The results demonstrated that
Runx2 induced several gelatin-degrading proteins, in
particular one with a molecular weight of ~140 kDa, the
identity of which remains to be determined (Figure 4A).
We further investigated whether Runx2 stimulates inva-
sion of C4-2B/Rx2
dox cells through Matrigel™,at i s s u e
basement membrane-like preparation containing lami-
nin, type IV collagen, heparan sulfate proteoglycans and
entactin. For convenient and accurate assessment of
cells that successfully invade through the Matrigel™
membrane, we transduced the C4-2B/Rx2
dox cells with a
lentivirus constitutively expressing luciferase. Parallel
trans-wells that do not contain Matrigel™ were employed
as migration controls. Cells were incubated in the
respective chambers in the presence or absence of Dox,
and the relative migration or invasion capacity was
assessed. Runx2 expression led to a 2.3-fold decrease in
cell migration, but a 4.3-fold increase in invasion
through Matrigel™, i.e., a ~10-fold increase in invasive-
ness after adjustment for the reduced cell migration
(Figure 4B). The increased invasiveness was further con-
firmed in an independent experiment by histological
staining (Figure 4C). In parallel experiments, expression
of Runx2-M in C4-2B cells showed no significant effects
on either migration or invasion (data not shown). Thus,
expression of transcriptionally active Runx2 is sufficient
to enhance the tissue invasion potential of C4-2B cells.
Runx2 induces cellular quiescence by reversibly inhibiting
G1/S cell cycle transition
The IPA™ analysis of Runx2 down-regulated genes indi-
cated their strong association with cell cycle and prolifera-
tion-related functions (Table 2B). Many of these down-
regulated genes, as well as several up-regulated genes,
shed light on the well-established anti-proliferative activity
of Runx2 [2,15-17,19]. Most striking was the > 19- and >
8-fold up-regulation of RASD1 and DUSP1, respectively
(Table 1). RASD1 belongs to the Ras superfamily of G-
proteins, and its expression in breast cancer suppressed
cell growth [92]. DUSP1, a.k.a. MAP kinase phosphatase 1
(MKP1), is a dual specificity (Thr/Tyr) protein phophatase
with anti-proliferative properties [93]. Among the most
important cell cycle regulatory genes inhibited by Runx2
was c-Myc, with a ~3-fold decrease at the mRNA level
(Table 1) and a corresponding significant decrease at the
protein level (Figure 3). In line with the down-regulation
of c-Myc, the mRNA encoding its cell cycle promoting
targets E2F2 and CDK2 were also down-regulated (Table
1). CDK2 protein was decreased below detectability
(Figure 3). To further characterize effects of Runx2 on
PCa cell proliferation, we first validated by RT-qPCR the
changes in the transcript levels of RASD1, DUSP1, c-Myc
and E2F2 in the day-2 samples (Figure 5A). Next, we
tested the effect of Runx2 on C4-2B cell proliferation by
performing MTT assays every 48 hours after Dox-
mediated Runx2 induction. Runx2 significantly restrained
cell proliferation (Figure 5B). By contrast, the transcrip-
tionally-inactive Runx2-M did not affect proliferation
(Figure 5C). Thus, Runx2 restrains PCa cell proliferation
via its transcriptional activation property.
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Figure 3 Runx2-regulated protein expression. C4-2B/Rx2
dox cells
were treated with Dox or vehicle control, and proteins extracted as
whole cell lysate (upper panel) or the supernatant (bottom panel)
were subjected to western blot analysis using the indicated
antibodies.
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Page 9 of 18To delineate the anti-proliferative effect of Runx2, we
tested its influence on apoptosis and cell cycle progres-
sion. Apoptosis was measured using succinyl-AMC, a
fluorogenic Caspase-3 substrate. Expression of Runx2,
but not Runx2-M, resulted in a transient 40% increase
in apoptosis on day 4 (Figure 5D), but this could not
account for the dramatic inhibition of cell proliferation
(Figure 5B). Instead, fluorescence activated cell-sorting
(FACS) analysis revealed a 2.2-fold decrease in the frac-
tion of cells in the S/G2/M phases of the cell cycle
within 24 hours of Dox treatment, and this effect per-
sisted on day 2 (Figure 5E). Notably, the cell cycle inhi-
bition preceded any change in apoptosis, indicating that
Runx2 restrained C4-2B cell proliferation by inhibiting
the G1/S phase transition of the cell cycle.
The prometastatic but anti-mitogenic properties of
Runx2 in PCa cells suggest that it may initially facilitate
metastasis, after which it must be degraded or antago-
nized (e.g. by co-repressors) to allow cell proliferation
and tumor growth. Therefore, we examined if the anti-
mitogenic effect of Runx2 was reversible by withdrawing
Dox from cultures after 48 hours of treatment (Figure
5F). Dox withdrawal led to substantial clearance of
Runx2 within two days, and undetectable Runx2 levels
after four days (Figure 5G). This resulted in resumption
of cell cycle progression (Figure 5H) and cell prolifera-
tion (Figure 5I). Thus, the Runx2-regulated gene net-
works induce reversible cellular quiescence by blocking
the G1/S phase transition of the cell cycle.
Generality and Network modeling of Runx2-regulated
genes with cancer-related functions
Our study is the first to provide genome wide analysis of
Runx2-regulated genes in PCa cells. Although we
focused on the bone metastasis-derived C4-2B cells,
similar responses to Runx2 were observed in the paren-
tal lymph node-derived LNCaP cells [38] (see additional
file 5) as well as in the unrelated bone metastatic 22RV1
PCa cells (see additional file 6) [94]. Furthermore, in
PC3
high and PC3
low cells with high and low levels of
Runx2, respectively, the expression of six randomly
selected Runx2 up-regulated genes from the present
study correlated with Runx2 expression (see additional
file 7). Together, these results suggest that our observa-
tions are relevant to various stages of PCa progression.
Among the 910 genes that Runx2 up- or down-regu-
lated by ≥2f o l d ,I P A ™ identified 248 genes related to
cancer with high statistical significance (p < 0.003; Table
2 and additional file 3). The IPA™ analysis, as well as
survey of literature on gene expression profiling in
osteoblasts and fibroblasts, further suggested that the
Runx2-regulated gene network in PCa (Figure 6) bears
little resemblance to its targets in mesenchymal cells
[43,83,95-97]. In fact, only five of the cancer-related
genes in our study have been previously reported as
Runx2 targets (MMP13, CEBPA, VEGF, SMAD3, and
SMAD6) and only six others are Runx1 and/or Runx3
targets (SKP2, CSF2, IL3, ACHE, IGFBP3, and HIPK2;
Figure 6). The remaining 234 genes are therefore novel
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Figure 4 Runx2 enhances the invasiveness of C4-2B cells. A) Zymography of supernatants from C4-2B/Rx2
dox cells treated with either Dox or
vehicle. Negatively-stained bands represent the activity of gelatin-degrading proteases. B) C4-2B/Rx2
dox/Luc cells were incubated in the top
chambers (inserts) of the Matrigel™ invasion system. Cell passage through inserts with and without Matrigel™ represent invasion and migration,
respectively. Identical number of cells was seeded in the indicated inserts for 24 hours and the cells that appeared on the bottom side (outside)
of the inserts were solubilized in lysis buffer and subjected to luciferase assay. C) The invasion of cells through the Matrigel™ membrane was
assessed by staining with Diff-Quick™ solution.
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Page 11 of 18Figure 6 Runx2-regulated cancer-related gene network. The 119 cancer-related genes showing a significant ≥2-fold response to Runx2 on
day 1 were subjected to the pathway analysis tool from Ingenuity Systems (IPA™). Direct relationships with Runx2 are shown as thick lines and
interactions with its paralogs Runx1 and Runx3 are shown as dashed lines. Red and blue fonts mark up- and down-regulated genes, respectively.
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Page 12 of 18Runx2-regulated genes related to cancer in general and
to metastasis in particular. The extensive Runx2-regu-
lated cancer-related gene network highlights Runx2 as a
viable target for the diagnosis, prognosis and treatment
of PCa.
Conclusions
Runx2, traditionally known for its master regulatory
roles in the chondro-osteoblast lineage, is emerging as a
prometastatic transcription factor [22,29,34,98-101]. The
Runx2 transcriptome in C4-2B cells documents gene
networks that control multiple aspects of metastasis.
Potentially contributing to local invasion and dissemina-
tion are the genes known to function in EMT, motility
and ECM degradation. Additionally, the prometastatic
function of Runx2 likely involves its target genes SDF-1,
CXCR7 and BSP, which promote homing and attach-
ment to bone. We also discovered Runx2 targets such
as CSF2 and SPHK1, osteoclast activators that likely
contribute to the most important alteration that occurs
i nt h eb o n em i c r o e n v i r o n m e n ti nr e s p o n s et oP C a
metastasis, namely enhanced bone turnover. During this
process, bone matrix components such as TGFß, BMPs
and calcium ions are released and further fuel tumor
growth and bone microenvironment modifications
[102-105]. The regulation of SPHK1 by Runx2 probably
potentiates additional aspects of the cancer phenotype,
including angiogenesis (a function assisted by the Runx2
targets VEGFA and EDN2) and drug resistance [77,79].
The anti-mitogenic activity of Runx2 is consistent with
the slow growth of PCa tumors, and may contribute to
drug resistance. We imagine that future anti-Runx2
drugs will be administered along with traditional che-
motherapy to eliminate cells that regain proliferative
capacity. Interestingly, Runx2 physically and functionally
interacts with the receptors for androgens and estrogens
[99,101]. Since these receptor proteins are targeted by
many drugs for prostate and breast cancer, it is impor-
tant to investigate their effects on Runx2-regulated tran-
scription. Moreover, development of selective estrogen
and androgen receptor modulators may benefit from
consideration of their effects on Runx2 and expression
of its target genes reported in the present study.
Methods
Cell culture reagents and antibodies
C4-2B cells were obtained from ViroMed Laboratories
(Minneapolis, MN). LNCaP and 22RV1 cells were from
ATCC (Rockville, MD, USA). PC3 cells were also
obtained from ATCC, but propagated for several years
in either our laboratory (PC3
low)o rt h a to fU S C ’sD r .
Pradip Roy-Burman (PC3
high). The cells were main-
tained in RPMI-1640 medium supplemented with 10%
T e tS y s t e mA p p r o v e dF B Sf r o mC l o n t e c h ,C A ,U S A .
Hygromycin B was purchased from Invitrogen, Carlsbad,
CA, USA and added to the growth medium at 50 μg/ml.
Doxycycline from Calibiochem, La Jolla, CA, USA was
used at 0.25 ug/ml unless otherwise stated, and an equal
volume of distilled water was used as vehicle control.
Mouse ANTI-FLAG® M2 monoclonal antibody for was
purchased from Sigma, St Louis, MO, USA. Mouse anti-
Runx2 was from Invitrogen, Carlsbad, CA, USA. The
anti-PIP antibody (ab 62363) was purchased from
abcam Inc., Cambridge, MA; and anti-GAPDH (V-18),
anti-TGFß-RIII (Sc 28975), and anti-SDF-1 (Sc-28876)
antibodies were purchased from Santa Cruz Biotechnol-
ogy Inc, Santa Cruz, CA, USA. The mouse monoclonal
anti-Myc and anti-VEGFA antibodies were developed
and kindly provided by USC’s Dr. Prakash S. Gill and
Dr. Young Hong, respectively. The mouse monoclonal
anti-Tubulin antibody, developed by Dr. Charles Walsh,
was obtained from the Developmental Studies Hybri-
doma Bank under the auspices of the NICHD and The
University of Iowa, Department of Biological Sciences,
Iowa City, USA.
Plasmid construction
The cDNA encoding mouse Runx2 (MASN isoform,
type-2), which is 97% identical to human type-2 Runx2
[1], was amplified using pcDNA3.0-Runx2 as template
and the Flag epitope was inserted during the PCR
amplification (see primers in additional file 8). The Flag-
Runx2 cDNA was initially cloned into the SpeI/MfeI-
digested lentiviral entry vector pEN_TmiRc3 (ATCC®
catalog: MBA-248), and the resulting plasmid was
recombined using Gateway® LR Clonase® II enzyme mix
(Invitrogen, Carlsbad, CA, USA) with the pSLIK (single
lentivector for inducible knockdown) destination vector
carrying a hygromycin resistance gene (ATCC® catalog:
MBA-237). The entry and destination vectors were
kindly provided by USC’s Dr. Elizabeth Lowler (Chil-
drens Hospital Los Angeles). The DNA-binding mutant
Runx2-M was constructed by site directed mutagenesis
of two arginine residues at positions 265 and 268
(GRSGRGK) known to contact DNA in the crystal
structure [40]. Lentiviral plasmid for constitutive Luci-
ferase expression pCCL-c-MNDU3c-Luc-PGK-eGFP was
kindly provided by USC’s Dr. Michael Kahn at the Zil-
kha Neurogenetic Institute.
Lentivirus production and infection
For packaging, the lentiviral expression plasmids were
cotransfected by the calcium chloride method into
HEK293T cells along with helper plasmids pMD.G1 and
pCMVR8.91[106,107]. Culture media containing viral
particles were harvested after 48-72 hours and used for
transduction of C4-2B cells in the presence of 8 μg/ml
Polybrene (Millipore Corp., MA, USA). After infection
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with 50 μg/ml of Hygromycin.
Transient transfection and Luciferase assays
Transient transfection and Luciferase assays were per-
formed essentially as described by Khalid et al. [99].
Briefly, 25,000 cells were plated in a 24-well plate 48
hours prior to transfection using Invitrogen’s Lipofecta-
mine™ LTX reagent according to manufacturer’s instruc-
tions. Cells were harvested and subjected to luciferase
assay using Luciferase Ass a ys y s t e mf r o mP r o m e g a ,
Madison, WI, USA.
High throughput gene expression measurement and
analysis
Gene expression profiling was performed using the
BeadChip™ platform (Illumina) and chip reference 8,
version 3 for humans, which contains 24,526 gene
probes and 664 negative control probes. Details of the
raw data processing and analysis are provided in the
additional file 9. Briefly, after background correction,
the normalized expression intensities for all probes
were subjected to a two-way analysis of variance
(ANOVA) and the resulting p-values were adjusted
for multiple testing using the Benjimini-Hochberg
method [108]. The differentially expressed probes
were further investigated using the Ingenuity Path-
ways Analysis package (IPA™; http://www.ingenuity.
com) to identify biological functions and disease cate-
gories that are significantly enriched among the differ-
entially expressed genes. Right-tailed Fisher’se x a c t
test as implemented in the IPA software was used to
calculate a p-value for the probability of each network
to be enriched for Runx2-regulated genes due to
chance alone. The microarray data has been deposited
to the GEO database with the accession code
GSE24261.
Preparation of conditioned medium and gelatin
zymography
C4-2B/Rx2
dox cells were cultured in 10 cm culture
dishes to 80% confluence, washed 3 times with RPMI-
1640 and treated with Dox in 10 mL of RPMI-1640
without FBS for 24 hrs. For zymography the 25 μl of the
conditioned media from Dox treated or control cells
were analyzed by 8% acrylamide gels containing 0.1% w/
v gelatin [109] After electrophoresis, the gel was washed
with 2.5% Triton X-100 and incubated in the developing
buffer (500 mM Tris-HCl, pH 7.8, 2 M NaCl, 50 mM
CaCl2) overnight to induce gelatin lysis. Gel was stained
by Coomasie blue-250. For western blot analysis of con-
ditioned media, 250 μl of the supernatant was TCA-pre-
cipitated and subjected to reducing SDS-PAGE analysis
using standard procedures.
In vitro invasion and migration assays
Invasion through Matrigel™ was assessed by incubating
20,000 luciferase-expressing cells at the top of 24 well
BD BioCoat™ Growth Factor Reduced Matrigel™ cham-
ber (BD Biosciences, MA, USA). Migration was assessed
using BD BioCoat™ Control Inserts. Cells that migrated
or invaded to the bottom compartment were visualized
by Diff-Quick™ staining kit (Baxter, MN, USA) or sub-
jected to luciferase assays for quantification. Invasion
index was defined as the percentage of cells that invaded
through Matrigel™ over those that migrated under the
same conditions but without the Matrigel™.
Proliferation, cell cycle and apoptosis
Cultures on different days were subjected to MTT
assay (Sigma, St Louis, MO) to measure viable cells in
culture. For cell cycle analysis, 2 × 10
5 to 1 × 10
6 cells
were harvested, washed twice with PBS (1 mL) at
room temperature and stored in absolute ethanol
(4 mL) for at least 24 hours. Pelleted cells were rehy-
drated in 5 mL PBS for 15 minutes, followed by stain-
ing with 1 mL of a propidium iodide (PI, Calibiochem,
La jolla, CA, USA) solution containing 3 μMP Ii n
incubation buffer (100 mM Tris, pH 7.4, 150 mM
NaCl, 1 mM CaCl2,0 . 5m MM g C l 2,0 . 1 %N o n i d e t ®P -
40). The cell suspension (1 mL) was subjected to fluor-
escence-activated cell sorting (FACScaliber, Becton
Dickinson, MA, USA) and each cell was assigned to
the G1, S, G2 or M phase of the cell cycle based on
the PI intensity and using the Multicycle v3.0 software
(Phoenix Flow Systems, San Diego, CA, USA). To
assess apoptosis, cells were lysed in caspase assay buf-
fer containing 50 mM HEPES (pH 7.5), 100 mM NaCl,
2 mM EDTA, 0.1% CHAPS, 10% sucrose, and 5 mM
DTT. Aliquots of crude cell lysate (50 μgp r o t e i n )w e r e
incubated with the caspase-3 substrate Ac-DEVD-
AMC (EMD/Calbiochem, La Jolla, CA, USA) at 37°C
for 30 min and the caspase-3 activity was quantified by
flow fluorimetry with excitation at 380 nm and emis-
sion at 440 nm using Victor3V™ from PerkinElmer,
Shelton, CT, USA.
Western blot analysis
Between 1 × 10
5 and 2 × 10
5 cells were washed once
with PBS and lysed with 200 μL of incubation buffer
[100 mM Tris (pH 7.4), 500 mM NaCl, 1 mM CaCl2,
0.5 mM MgCl2, 0.1% Nonidet® P-40] supplemented with
Complete™ protease inhibitor mix (Roche Diagnostics,
Indianapolis, IN, USA). Aliquots of 40 μg cell lysate
were mixed with an equal volume of Laemmli buffer
a n dp r o t e i n sw e r er e s o l v e db y1 0 %S D S - P A G E ,t r a n s -
ferred to Amersham Hybond™-P PVDF (GE Healthcare,
Piscataway, NJ, USA) membranes, and visualized using
respective antibodies and the Western Lightning™ Plus-
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Page 14 of 18ECL kit (PerkinElmer Inc, Waltham, MA, USA) followed
by exposure to X-ray film (ISCBioExpress®, Kaysville,
UT, USA).
RT-qPCR
Total RNA was isolated using Aurum Total RNA kit
(Bio-Rad Laboratories Inc., Hercules, CA, USA) follow-
ing the manufacturer’s recommendations and 1 μgw a s
reverse transcribed using the Superscript III kit (Invitro-
gen, CA, USA). The cDNA was subjected to real-time
PCR amplification using iQ SYBR Green Supermix and
a Opticon™2 real time PCR machine from Bio-Rad, Her-
cules, CA. The sequences of primers for amplification of
the cDNA of interest and the control GAPDH are listed
in the additional file 8.
GEO accession code for the microarray data:
GSE24261
Additional material
Additional file 1: ANOVA analysis of the microarray data. List of all
probes with the microarray gene expression data in log scale (base 2)
along with the Fold change, P-values and gene annotations.
Additional file 2: Runx2-regulated genes involved in cellular
metabolism. List of genes with functions in cellular metabolism, their
fold changes, and known functions.
Additional file 3: Runx2 -regulated genes involved in cancer. List of
256 genes with established roles in cancer.
Additional file 4: E-Cadherin expression in C4-2B/Rx2
dox cells upon
Runx2 expression. Western blot and RT-qPCR analysis of C4-2B/Rx2
dox
cells in response to Runx2 expression.
Additional file 5: Generation and characterization of LNCaP/Rx2
dox
cells. RT-PCR to detect Runx2 transcript in PC3, C4-2B, and LNCaP cells.
Proliferation of the LNCaP/Rx2
dox cells by using MTT, and RT-qPCR
analysis of Runx2-regulated genes.
Additional file 6: Generation and characterization of 22RV1/Rx2
dox
cells. Western blot analysis of Dox-induced Runx2, and MTT based
proliferation analysis of 22RV1/Rx2
dox cells in response to Runx2
expression.
Additional file 7: Expression of PGC, CST7, S100A4, SDF-1, CSF2,
and DUSP1 in two PC3 sub-lines with different Runx2 levels. RT-
qPCR analysis using PC3
high and PC3
low cells to examine the expression
of Runx2-regulated genes.
Additional file 8: List of primers used in the present study to PCR-
amplify the indicated gene sequences. Nucleotide sequence of
primers.
Additional file 9: Bioinformatics analysis of the microarray data.
Detailed description of microarray quality control and data processing
(such as quality control, normalization and box/density plots); and
methodology employed for the identification of differentially expressed
probes.
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